[Pharmacokinetic aspects of tuberculosis therapy with a fixed combination of rifampicin, isoniazide and pyrazinamide].
The here described investigations show correspondingly that the administration of isoniazid, rifampicin and pyrazinamide in a fixed combination of the administration of the individual substances is bioequivalent under pharmacokinetic aspects. Further investigations on large populations of patients must, however, still confirm whether or not the advantages of the fix combination striven for or theoretically to be expected can be proved in practice.
Schaberg
T
T
Pneumologie I (Infektiologie und Immunologie), Krankenhaus Zehlendorf-Heckeshorn, Berlin.
Lode
H
H
D001682:Biological Availability; D004359:Drug Therapy, Combination; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011718:Pyrazinamide / Q000008:administration & dosage* / Q000493:pharmacokinetics; D012293:Rifampin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014397:Tuberculosis, Pulmonary / Q000097:blood / Q000188:drug therapy*
D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin
Pharmakokinetische Aspekte der Tuberkulosetherapie mit einer fixen Kombination von Rifampicin, Isoniazid und Pyrazinamid.